Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that Lonna J. Williams, CEO will speak at the 6th Annual Neurotech Investing and Partnering Conference to be held in San Francisco, CA at the St. Regis Hotel on May 9th and 10th.  

Ms. Williams, a clinical diagnostics industry veteran, will participate on a panel entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, Vice President, Bay City Capital. The panel will discuss the most promising next generation diagnostics, devices and treatments for neuropsychiatric disorders such as depression, schizophrenia, anxiety, addiction and others.

Ridge Diagnostics develops and sells blood tests which aid in the diagnosis and management of clinical depression or Major Depressive Disorder.  For the first time, a blood test provides clinicians and patients with objective, biologically based, diagnostic information to manage and treat this disorder.    Blood test results are intended to augment the current tools used for neuropsychiatric diagnosis and patient management.  Additional tests are in development for antidepressant efficacy monitoring and adolescent depression.

Ridge Diagnostics, Inc. Ridge Diagnostics is a neurodiagnostic company developing and marketing blood-based tests to diagnose and monitor neuropsychiatric disorders.  Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD).   The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and Hyper-Mapping technology.  The testing services are provided by the Ridge owned CLIA laboratory. The company is located in San Diego, CA and Research Triangle Park, NC.   www.ridgedx.com

Neurotech Investing and Partnering Conference. The premier partnering and investing conference where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry. Find out about next generation drugs, devices and diagnostics for Alzheimer's, addiction, anxiety, depression, Huntington's, ALS, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, Parkinson's and more.

SOURCE Ridge Diagnostics, Inc.